Abstract
COX-2 inhibitors are equally as efficacious as the non-selective NSAIDs for the treatment of postoperative pain, but have the advantages of a better gastrointestinal side-effect profile as well as a lack of antiplatelet effects. There have been recent concerns regarding the cardiovascular side effects of COX-2 inhibitors. Nonetheless, they remain a valuable option for postoperative pain management. The pharmacology of these agents and available studies are reviewed.
Keywords: Celecoxib, parecoxib, postoperative pain
Current Topics in Medicinal Chemistry
Title: COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Volume: 7 Issue: 3
Author(s): Noor M. Gajraj
Affiliation:
Keywords: Celecoxib, parecoxib, postoperative pain
Abstract: COX-2 inhibitors are equally as efficacious as the non-selective NSAIDs for the treatment of postoperative pain, but have the advantages of a better gastrointestinal side-effect profile as well as a lack of antiplatelet effects. There have been recent concerns regarding the cardiovascular side effects of COX-2 inhibitors. Nonetheless, they remain a valuable option for postoperative pain management. The pharmacology of these agents and available studies are reviewed.
Export Options
About this article
Cite this article as:
Gajraj M. Noor, COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management, Current Topics in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/156802607779941323
DOI https://dx.doi.org/10.2174/156802607779941323 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews New Trends in Thromboxane and Prostacyclin Modulators
Current Medicinal Chemistry Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry Nocturnal Blood Pressure Abnormalities in Obstructive Sleep Apnea - Clinical Predictors
Current Respiratory Medicine Reviews New Anti-Anginal Drugs: Ranolazine
Cardiovascular & Hematological Agents in Medicinal Chemistry The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Current Pharmacogenomics and Personalized Medicine Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Diabetes in Racial and Ethnic Minorities in the United States: Individualizing Approaches to Diagnosis and Management
Current Diabetes Reviews Editorial: Signalling Pathways in Virus-caused Cancers
Current Cancer Drug Targets Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design